Importance of predictive biomarkers related to Pharmacogenetics in breast cancer and prostate: a systematic review

Authors

DOI:

https://doi.org/10.33448/rsd-v10i3.13713

Keywords:

Carcinogenesis; Pharmacogenomics; Biomarker; Treatment.

Abstract

Pharmacogenetics allows to verify the genetic polymorphisms that influence the success of an oncological pharmacotherapy, therefore, the need for progression in the pharmacogenomic oncological field is evident. This study aims to describe the importance of predictive biomarkers related to pharmacogenetic breast and prostate cancer through a literature review. The search for original articles took place between February and November 2020 in databases such as Pubmed, Scielo, Medline and search directories such as Google Scholar. As for the inclusion criteria, the original articles in English, Portuguese and Spanish published between 2010 and 2020 were included. The search result found 102 articles on the subject, 36 excluded because they were review articles, 22 excluded after reading the abstract and 13 excluded because they did not align with the theme. 31 original articles were selected for which the authors prove the importance of validating independent studies on predictive values ​​of biomarkers for breast and prostate cancer. The conclusion of the analyzed studies suggests that the use of biomarkers makes it possible to predict responses to clinical treatment, appropriate therapeutic conduct where they are associated with better treatment results.

References

Almeida, J. R. C., Pedrosa, N. L., Leite, J. B., Fleming, T. R. P., Carvalho, V. H. & Cardoso, A. A. A. (2007). Tumor Markers: Literature Review. Revista Brasileira De Cancerologia, 53(3), 305-316.

Álvarez, M. P., Marcos, V. E., García, B. B. & Isidoro, G. M. (2019). Farmacogenómica: La Medicina Personalizada. Revista Del LaboratorioClínico, 12, 147-154.

Antonarakis, E. S., Lu, C.,Wang, H., Luber, B., Nakazawa, M., Roeser , J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., Lotan, T. L., Heng, Q., Marzo, A. M., Isaacs J. T., Isaacs, W. B., Nadal, R., Paller, C. J., Denmeade, S.R., Carducci, M. A., Eisenberger, M. A. & Luo, J. (2014). Ar-V7 And Resistance to Enzalutamide and Abiraterone In Prostate Cancer. The New England Journal of Medicine, 371(11), 1028-1038.

Antonarakis, E. S., Lu, C., Luber, B., Wang, H., Chen, Y., Zhu, Y., Silberstein, J. L., Taylor, M. N., Maughan, B. L., Denmeade, S. R., Pienta, K. J., Paller, C. J., Carducci, M. A., Eisenberger, M. A. & Luo J. (2017). Clinical Significance of Androgen Receptor Splice Variant-7 Mrna Detection in Circulating Tumor Cells Of Men Withmetastatic Castration-Resistant Prostate Cancer Treated With First- And Second-Line Abiraterone And Enzalutamide. Journal of Clinical Oncology, 35 (19), 2149-2156.

Armstrong, C. M., Liu, C., Lou, W.; Lombard, A. P., Evans, C. P. and Gao, A. C. (2017). Microrna‐181a PromotesDocetaxelResistance In ProstateCancerCells. The Prostate, 77 (9), 1020-1028.

Asiaf, A., Ahmad, S. T., Arjumand, W. & Zargar, M. A. (2018). Micrornas In Breast Cancer: Diagnostic and Therapeutic Potential. Microrna And Cancer, 1699, 23–43.

Badani, K. K., Thompson, D. J. S., Brown, G., Holmes, D., Kella, N., Albala, D., Singh, A., Buerki, C., Vicioni, E D. & Hornberger, J. (2015). Effect of A Genomic Classifier Test on Clinical Practice Decisions for Patients with High-Risk Prostate Cancer After Surgery. Bju International, 115 (3), 419-429.

Badani, K. K., Thompson, D. J. S., Buerki, C., Davicioni, E., Garrison, J., Ghadessi, M., Mitra, A.P., Wood, P.J. & Hornberger, J. (2013). Impact of A Genomic Classifier of Metastatic Risk on Postoperative Treatment Recommendations for Prostate Cancer Patients: A Report from The Decide Study Group. Oncotarget, 4 (4), 600-609.

Bownes, R. J., Turnbull, A. K., Martinez-Perez, C., Cameron, D. A., Sims, A. H. & Oikonomidou, O. (2019). On-Treatment Biomarkers Can Improve Prediction of Response to Neoadjuvant Chemotherapy In Breast Cancer. Breast Cancer Research, 21 (1), 73.

Carrasco, R. A., Stamm, N. B., Marcusson, E., Sandusky, G., Iversen, P. & Patel, B. K. (2011). Antisense Inhibition of Survivin Expression As A Cancer Therapeutic. Molecular Cancer Therapeutics, 10 (2), 221–232.

Crawford, E. D., Scholz, M. C., Kar, A. J., Fegan, J. E., Haregewoin, A., Kaldate, R. R. & Brawer, M. K. (2014). Cell Cycle Progression Score and Treatment Decisions in Prostate Cancer: Results from An Ongoing Registry. Current Medical Research and Opinion, 30 (6), 1025-1031.

Ding, J., Yang, Y., Jiang, L., Wu, W. & Shao, Z. (2017). Predictive Factors of Pathologic Complete Response in Her2-Positive And Axillary Lymph Node Positive Breast Cancer After Neoadjuvant Paclitaxel, Carboplatin Plus With Trastuzumab. Oncotarget, 8 (34), 56626-56634.

Estatísticas De Câncer. (2020). Instituto Nacional de Câncer. https://www.inca.gov.br/numeros-de-cancer. Acessed: January 2021.

Fan, L., Yang, Y., Chi, C., Ma, X., Wang, R., Gong, Y., Zheng, H., Pan, J., Zhu Y., Dong B. & Xue, W. (2019). Neuroendocrine Differentiation Markers Guide Treatment Sequence Selection in Metastatic Castration-Resistant Prostate Cancer. The Prostate, 79 (6), 567-573.

Fricke, G., Jung, G. H.; Lerena, A. & López, L. M. (2018). Pharmacogenetics of Adverse Reactions to Antiepileptic Drugs. Neurología (EnglishEdition), 33 (3), 165-176.

García-Vázquez, R., Marchat, L. A., Ruíz-García, E., De La Vega, H.A., Meneses-García, A., Arce-Salinas, C., Bargallo-Rocha, E., Carlos-Reyes, Á., López-González, J.S., Pérez-Plasencia, C., Ramos-Payán, R., Aguilar-Medina, M. & López-Camarillo, C. (2019). Microrna-143 Is Associated with Pathological Complete Response and Regulates Multiple Signaling Proteins in Breast Cancer. Technology in Cancer Research & Treatment, 18, 1-11.

Genitsch, V., Zlobec, I., Seiler, R., Thalmann, G.N. & Fleischmann, A. (2017). Neuroendocrine Differentiation In Metastatic Conventional Prostate Cancer Is Significantly Increased In Lymph Node Metastases Compared To The Primary Tumors. International Journal of Molecular Sciences, 18 (8), 1640.

Haddad, C.F. (2010). Trastuzumab In Breast Cancer. Feminina, 38 (2), 73-78.

Hao, S., Tian, W., Zhao, J., Chen, Y., Zhang, X., Gao, B., He, Y. & Luo, D. (2020). Analysis of Circulating Tumor Dna To Predict Neoadjuvant Therapy Effectiveness and Breast Cancer Recurrence. Journal of Breast Cancer, 23 (4), 373-384.

Jung, K., Miller, K., Wirth, M., Albrecht, M. & Lein, M. (2011). Bone Turnover Markers as Predictors Of Mortality Risk In Prostate Cancer Patients With Bone Metastases Following Treatment With Zoledronic Acid. European Urology, 59 (2011), 604-612.

Kim, S. K., Jung, W. H. & Koo, J. S. (2014). Yes-Associated Protein (Yap) Is Differentially Expressed In Tumor And Stroma According To The Molecular Subtype Of Breast Cancer. International Journal of Clinical and Experimental Pathology, 7 (6), 3224-3234.

Klopp-Schulze, L., Mueller-Schoell, A., Neven, P., Koolen, S., Mathijssen, R., Joerger, M. & Kloft, C. (2020). Integrated Data Analysis Of Six Clinical Studies Points Toward Model-Informed Precision Dosing Of Tamoxifen. Frontiers in Pharmacology, 11, 283.

Kurozumi, S., Inoue, K., Takei, H., Matsumoto, H., Kurosumi, M., Horiguchi, J. & Oyama, T. (2015). Er, Pgr, Ki67, P27 Kip1, And Histological Grade As Predictors Of Pathological Complete Response In Patients With Her2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy Using Taxanes Followed By Fluorouracil, Epirubicin, And Cyclophosphamide Concomitant With Trastuzumab. Bmc Cancer, 15, 622.

Lara, M. P., Jr.; Ely, B., Quinn, Q. I., Mack, P.C., Tangen, C., Gertz, E., Twardowski, P. W., Goldkorn, A., Hussain, M., Vogelzang, N. J., Thompson, I. M. & Loan. M. D. V. (2014). Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients with Skeletal Metastases: Results from Swog 0421. Journal of The National Cancer Institute, 106 (4), 1-9.

Manica, G. C., Ribeiro, C. F., Oliveira, M. A., Pereira, I. T., Chequin, A., Ramos, E. A., Klassen, L. M., Sebastião, A. P., Alvarenga, L. M., Zanata, S. M., Noronha, L., Rabinovich, I., Costa, F. F., Souza, E. M. & Klassen, G. (2017). Down Regulation of Adam33 As A Predictive Biomarker of Aggressive Breast Cancer. Scientific Reports, 7, 44414.

Markowshi, M.C., Silberstein, J.L., Eshleman, J.R., Eisenberger, M.A., Luo, J. & Antonarakis, E.S. (2017). Clinical Utility of Clia-Grade Ar-V7 Testing In Patients With Metastatic Castration-Resistant Prostate Cancer. Na American Society of Clinical Oncology Journal, 1, 1-9.

Michalopoulos, S. N., Kella, N., Payne, R., Yohannes, P., Singh, A., Hettinger, C., Yousefi, K. & Hornberger, J. (2014). Influence of A Genomic Classifier On Post-Operative Treatment Decisions In High-Risk Prostate Cancer Patients: Results From The Pro-Act Study. Current Medical Research and Opinion, 30 (8), 1547-1556.

Miyamoto, T. D., Lee, R. J.; Kalinich, M., Licausi, J. A., Zheng, Y., Chen, T., Milner, J. D., Emmons, E., Ho, U., Broderick, K., Silva, E., Javaid, S., Kwan, T. T., Hong, X., Dahl, Dm., Mcgovern, F. J., Efstathiou, J. A., Sequist, L. V., Kapur, R., Wu, C., Stott, S. L., Ting, D. T., Giobbie-Hurder, A., Toner, M., Maheswaran, S. & Haber, D.A. (2018). An Rna-Based Digital Circulating Tumor Cell Signature Is PredictiveOf Drug Response and Early Dissemination In Prostate Cancer. Cancer Discovery, 8 (3), 288-303.

Moul, J. W., Chen, D. Y. T., Trabulsi, E. J., Warlick, C. A., Ruckle, H. C., Porter, J. R., Yoshida, J. S., Adams, G. W., Kella, N., Matsunaga, G. S., Bans, L. L., Sarno, M. J., Mcdermed, J. E., Triebell, M.T. & Reynolds, M. A. (2014). Impact of Nadia ProsvuePsa Slope on Secondary Treatment Decisions After Radical Prostatectomy. Prostate Cancer And Prostatic Diseases, 17 (3), 280-285.

Santos, B. G. Q. (2017). A Aplicação Da Farmacogenética Em Contexto De Farmácia Hospitalar. Tese Instituto Universitário Egas Moniz.

Santos, S. L. F., Pessoa, C. V., Alves, H. H. S., Oliveira, C. P. A. & Barros, K. B. N. T. (2016). Pharmacogenética Aplicada À Oncologia: Realidade Brasileira E Perspectivas Na Prática Clínica. Boletim Informativo Geum, 7 (3), 49-55.

Sandler, H., Klein, E. A., Black, P., Seiler, R., Tomlins, A., Chinnaiyan, A. M., Jenkins, R. B., Davicioni, E., Ross, A. E., Schaeffer, E. M., Nguyen, P. L., Carroll, P. R., Karnes, R. J., Spratt, D. E. & Feng, F. Y. (2017). Associations of Luminal and Basal Subtyping of Prostate Cancer with Prognosis And Response To Androgen Deprivation Therapy. Jama Oncology, 3 (12), 1663-1672.

Saxby, H., Mikropoulos, C. & Boussios, S. (2020). An Update on The Prognostic and Predictive Serum Biomarkers In Metastatic Prostate Cancer. Diagnostics, 10 (8), 549.

Shi, G., Ye, D., Yao, S., Zhang, S., Dai, B., Zhang, H., Shen, Y., Zhu, Y., Zhu, Y., Xiao, W. & Ma, C. (2010). Involvement of Microrna-21 In Mediating Chemo-Resistance to Docetaxel in Androgen-Independent Prostate Cancer Pc3 Cells. Acta Pharmacologica Sinica, 31(7), 867-873.

Schilling, M., Silva, I., Opitz, S., Borges, M., Koifman, S. & Koifman, R. (2017). Breast Cancer Awareness among Women in Western Amazon: a Population Based Cross-Sectional Study. Revista Da Ásia-Pacífico Sobre Prevenção Do Câncer: Apjcp, 18(3), 847-856.

Shokouh, T. Z., Ezatollah, A. & Barand, P. (2015). Interrelationships Between Ki67, Her2/Neu, P53, Er, And Pr Status and Their Associations with Tumor Grade and Lymph Node Involvement In Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study. Medicine, 94 (32), 1359.

Shore, N. D., Kella, N., Moran, B., Boczko, J., Bianco, F. J., Crawford, E. D., Davis, T., Roundy, K. M., Rushton, K., Grier, C., Kaldate, R., Brawer, M. K. & Gonzalgo, M. L. (2016, march). Impact of The Cell Cycle Progression Test on Physician And Patient Treatment Selection For Localized Prostate Cancer. The Journal of Urology, 195 (3), 612-618.

Someya, M., Hori, M., Gocho, T., Nakata, K., Tsuchiya, T., Kitagawa, M., Hasegawa, T., Fukushima, Y. & Sakata, K. (2018). Prediction of Acute Gastrointestinal And Genitourinary Radiation Toxicity In Prostate Cancer Patients Using Lymphocyte Microrna. O Japanese Journal of Clinical Oncology, 48 (2), 167-174.

Sumoza-Toledo, A., Espinoza-Gabriel, M.I. & Montiel-Condado, D. (2016). Evaluation of The Trpm2 Channel As A Biomarker In Breast Cancer Using Public Databases Analysis. Boletín Médico Del Hospital Infantil De México (English Edition), 73(6), 397-404.

Tan, Q. X., Qin, Q.H., Yang, W.P., Mo, Q.G. & Wei, C.Y. (2014). Prognostic Value of Ki67 Expression In Hr-Negative Breast Cancer Before And After Neoadjuvant Chemotherapy. International Journal of Clinical and Experimental Pathology, 7 (10), 6862-6870.

Zhao, S. G., Chang, S. L., Erho, N., Yu, M., Lehrer, J., Alshalalfa, M., Speers, C., Cooperberg, M. R., Kim, W., Ryan, C. J., Den, R. B., Freedland, S. J., Posadas, E.,

Zhou, J., Le, K., Xu, M., Ming, J., Yang, W., Zhang, Q., Lu, L., Xi, Z., Ruan, S. & Huang, T. (2020). Cxcr4 Antagonist Amd3100 Reverses the Resistance To Tamoxifen In Breast Cancer Via Inhibiting Akt Phosphorylation. Molecular Therapy Oncolytics, 18, 161–170.

Zhou, J., Li, W., Ming, J., Yang, W., Lu, L., Zhang, Q., Ruan, S. & Huang, T. (2020). High Expression of Traf4 Predicts Poor Prognosis In Tamoxifen-Treated Breast Cancer And Promotes Tamoxifen Resistance. Anti-Cancer Drugs, 31 (6), 558–566.

Downloads

Published

24/03/2021

How to Cite

MENEZES, E. da S.; CARNEIRO, E. T. F.; ALMEIDA, M. K. C. de .; SANT’ ANNA, C. de C. Importance of predictive biomarkers related to Pharmacogenetics in breast cancer and prostate: a systematic review. Research, Society and Development, [S. l.], v. 10, n. 3, p. e51810313713, 2021. DOI: 10.33448/rsd-v10i3.13713. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/13713. Acesso em: 14 apr. 2021.

Issue

Section

Agrarian and Biological Sciences